NURIFLEX-HOLDINGS
6.1.2022 18:02:07 CET | Business Wire | Press release
NuriFlex Holdings Inc. (“NuriFlex Holdings ”) announced that it has signed a memorandum of understanding (“MoU ”) with Talken GmbH (“Talken ”). The two companies intend to collaborate in the metaverse token project and the multichain decentralized NFT wallet and its platform (“Project”) in various regions based on robust technology and business development capabilities of the parties.
One of NuriFlex Holdings’ businesses involves the design and development of a blockchain-based metaverse ecosystem to offer various virtual worlds and related digital experiences for various services. NuriFlex Holdings is currently investing in the metaverse project that is expected to launch this year, offering global users participation in its virtual metaverse world where they can create and interact with other users like in real life.
Talken GmbH provides a service called ‘Talken’, which is a multi-chain decentralized NFT wallet supported by one of the largest Korean communities. It is a seamlessly interoperable multi-chain NFT Suite, where K-pop stars, artists, and influencers can mint, auction, store, and trade NFTs. Talken NFT Suite offers various products for every NFT lifecycle stage such as NFT wallet, NFT marketplace, simple NFT minting tool and more.
“We are excited to partner and collaborate with Talken GmbH on our metaverse and NFT platform projects. The blockchain technology experience and business development capabilities that NuriFlex Holdings and Talken GmbH bring together will be a great advantage to successfully accomplish new business opportunities and the initial step to our future token projects,” said Songman Cho, Chairman of NuriFlex Holdings Inc.
“We hope this will be the first of many partnerships to come between Nuri Group and Talken. I trust there will be many synergies to be made between Nuri’s solution for blockchain-based digital services and Talken’s unique multichain NFT platform,” said Minsu Ju, Chief Executive Officer of Talken GmbH.
About NuriFlex Holdings Inc.
Located in Vancouver, BC, Canada, NuriFlex Holdings Inc. is a parent company to the Nuri Group of companies, including NuriFlex Inc. in the USA and NuriFlex Co., Ltd. in South Korea. The NuriFlex Group of companies utilize telecommunication technologies and applications to supply a simple, convergent solution for the utilities industry, payment solution and blockchain-based digital service platform. We provide a complete energy IoT solution which enhances the utility of connected micro and smart grids throughout our clients’ systems. The blockchain embedded solution and service will be NuriFlex Group’s next-generation business. Our existing solutions will be integrated with our blockchain technology to make us one of the top integrated solution providers in the international market. Learn more at www.nuri.ca
About Talken GmbH
Talken is the multi-chain decentralized NFT wallet with the largest community. It is a seamlessly interoperable multi-chain NFT Suite, where K-pop stars, artists, and influencers can mint, auction, store, and trade NFTs. Talken is an open NFT ecosystem bridging untapped NFT enthusiasts in Korea to Talken’s native NFTs and other famous NFTs by protocols such as NBA TopShot, Rarible, OpenSea, and more. Our mission is to push for an inclusive and border-less NFT expansion and empower digital creators and collectors with better tools and services to bring NFT mainstream. Learn more at www.talken.io
View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005002/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom